anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Respiratory droplets, naturally produced during expiration, can transmit pathogens from infected individuals. Wearing a face mask is crucial to prevent such transmission, yet the perception of dyspnea and uncomfortable breathing remains a common concern, particularly during epidemics. The aim of this study was to investigate the impact of face mask use on the perception of dyspnea, cardiopulmonary parameters, and facial temperature during physical activity. A randomized crossover study was conducted on healthy adults at a physiology laboratory located in the Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia, in November 2022. Participants underwent five stages of physical exercise tests based on the Bruce Protocol under three conditions: without any face mask (control), wearing a surgical mask, and an N95 mask, forming the study's main groups. Dyspnea perception (measured by the Modified Borg Dyspnea Scale), cardiopulmonary parameters (heart rate, oxygen saturation, respiratory rate, blood pressure, and mean arterial pressure) and facial temperature were measured before the exercise test (pre-workout), at the end of stage 1, 2, 3, 4, 5, and after the whole exercise test (post-workout). A two-way repeated measures ANOVA was conducted, considering two factors: the type of mask (control, surgical mask, N95 mask) and the various stages of the exercise test. A total of 36 healthy adults were included in the study. We found that dyspnea perception was much worse in the N95 mask group, particularly during vigorous exercise. There was no significant difference between groups in cardiopulmonary parameters. However, participants wearing N95 had a greater supralabial temperature than those wearing surgical masks or no mask at all. It is recommended to undertake a more in-depth evaluation of cardiopulmonary physiological measures.
Pasteurellosis is a common zoonotic infection that occurs after an animal bite or scratch (B/S). We compared the clinical features of six patients with non-B/S pasteurellosis with those of 14 patients with B/S infections. Pasteurella multocida was identified with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in all six non-B/S infections, whereas 13 of the 14 B/S infections were identified with diagnostic kits. The non-B/S infections were pneumonia (n = 3), skin and soft tissue infections (n = 2), and bacteremia (n = 1). Pneumonia occurred in two patients with underlying pulmonary disease, whereas ventilator-associated pneumonia developed in one patient with cerebral infarction. Pasteurella multocida was isolated from a blood specimen and nasal swab from a patient with liver cirrhosis (Child-Pugh class C) and diabetes. Cellulitis developed in one patient with diabetes and normal-pressure hydrocephalus, who had an open wound following a fall, and in one patient with diabetes and a foot ulcer. Three patients with non-B/S infections had no pet and no episode of recent animal contact. The rate of moderate-to-severe comorbidities was significantly higher in patients with non-B/S infections than in those with B/S infections (100% and 14.3%, respectively, p < 0.001). In conclusion, non-B/S infections can develop in patients with chronic pulmonary disease, invasive mechanical ventilation, or open wounds, or who are immunocompromised, irrespective of obvious animal exposure. In contrast to B/S infections, non-B/S pasteurellosis should be considered opportunistic.
An aspect of the present disclosure provides a synergistic herbal composition that exhibits an anti-proliferative activity, the composition including: therapeutically effective amount of Neem (Azadirachta spp.); and therapeutically effective amount of Mustard (Brassica spp.). In an embodiment, the composition includes Neem (Azadirachta spp.) in an amount ranging from about.25% to about 99% by weight of the composition. In an embodiment, the composition includes mustard (Brassica spp.) in an amount ranging from about.25% to about 99% by weight of the composition. In an embodiment, the composition further includes therapeutically effective amount of any or a combination of: an extract of myrrh, an extract of lavender, an extract of turmeric, an extract of chamomile, germanium or analogue thereof and cow urine. The composition further comprises camphor and bees wax and any other natural, synthetic or pharmaceutically accepted excipient or combination thereof.
Vasopressors are a mainstay of therapy for patients with septic shock to achieve and maintain hemodynamic stability.1 Both weight-based and non-weight-based dosing recommendations exist with no clear evidence that one is better than the other.3-10 However, in light of the obesity epidemic and emerging evidence regarding the dangers of excessive catecholamine exposure, an evaluation of dosing practices is warranted. The aim of this study is to determine whether clinical outcomes differ between patients receiving weight-based and non-weight-based vasopressor dosing strategies for septic shock. This is a multicenter, retrospective chart review. Patients admitted to MDMC and MCMC from 4/1/2017-8/31/2019 will be identified through the electronic medical record utilizing ICD codes for sepsis and septic shock. Patients meeting study inclusion criteria will be analyzed as described below. Outcomes will be assessed between patients receiving WBVP and NWBVP with planned subgroup analysis in each group between patients with BMI \< 30, 30-49, and \> 50.
In particular, this study will investigate the beneficial effects of long-term (8 weeks) supplementation with ACRB on fasting and postprandial levels of plasma triglycerides, as well as other parameters of lipid and glucose homeostasis and inflammation. Postprandial changes will be evaluated after consumption of a high-fat meal.

Subjects will receive either a: i) placebo (control),or ii) ACRB product for 8 weeks. At the beginning and at the end of the 8-week period, subjects will be submitted to a metabolic challenge consisting of consuming a high-fat meal after receiving the study product (placebo, ACRB). The high-fat meal will consist of English muffin bread, sausage, egg and cheese, obtained from US market with carotenoid-free palm oil added to bring the total dietary fat to the desired level. The total weight of the high-fat meal will be 320 g with 70.5 g of fat (29.8 g of saturated fat), 270 mg of cholesterol, 65 g carbohydrate, 5.2 g sugar, and 33 g protein. The total energy content of the high-fat meal will be 1,026 Kcal with a total of 62% energy originated from fat, 25% from carbohydrates and 13% from protein. Blood will be taken by venipuncture before (baseline, 0 h) and 0.25, 0.5, 1, 2, 3 and 5 h after consumption of both the high-fat meal and the study product. Plasma will be collected and chylomicrons and peripheral blood monocytes (PBMCs) will be isolated. Blood pressure and skin carotenoid content will be measured. Subjects will be also asked to collect feces before starting and at the end of the 8 week period.
BACKGROUND: One of the probable causes of statin myotoxicity is an imbalance between protein synthesis and degradation. These processes are regulated by the PI3K/Akt/mTOR pathway and the ubiquitin‒proteasome system (UPS). The aim of this study was to assess whether the effects of atorvastatin on PI3K/Akt/mTOR pathway downstream proteins, the FoxO3a transcription factor and the UPS genes, i.e., MuRF-1 and MAFbx, depend on muscle fibre type.
METHODS AND RESULTS: Atorvastatin (50 mg/kg) was administered to Wistar rats. The levels of selected PI3K/Akt/mTOR pathway proteins were assayed via Western blotting, whereas MuRF-1, MAFbx and FoxO3a mRNA levels were measured using reverse transcription quantitative polymerase chain reaction (RT‒qPCR). Gomöri trichrome staining was performed to assess skeletal muscle pathology. A decrease in the P-Akt/Akt ratio was observed in the gastrocnemius muscle (MG), whereas an increase in the P-Akt/Akt ratio was observed in the soleus muscle (SOL). FoxO3a gene expression increased in the SOL and extensor digitorum longus (EDL) muscles. MuRF-1 gene expression increased in the MG, and MAFbx expression increased in the EDL. No histopathological changes were observed in any of the tested muscles.
CONCLUSIONS: In the absence of overt muscle damage, atorvastatin decreased the P-Akt/Akt ratio in the MG, indicating an increase in inactive Akt. Consistent with the decrease in Akt activation, rpS6 phosphorylation decreased. In SOL, atorvastatin increased the P-Akt/Akt ratio, indicating Akt activation. P-FoxO3a and the P-FoxO3a/FoxO3a ratio increased, suggesting that FoxO3a inactivation occurred. Moreover, in the SOL, atorvastatin did not affect the expression of atrophy-related genes. These findings indicate that atorvastatin has no adverse effect on the Akt pathway in the SOL. Our results showed that the effects of atorvastatin on the Akt signalling pathway and atrophy-related gene expression depend on muscle type.
This systematic review and meta-analysis evaluate the impact of ultrasound-guided subsheath versus extrasheath sciatic nerve blocks on postoperative wound pain in tibial and foot surgeries, crucial for effective pain management and patient recovery. Adhering to PRISMA guidelines, this study used a PICO framework, focusing on patients undergoing tibial and foot surgeries and comparing the efficacy and safety of subsheath and extrasheath sciatic nerve blocks. The literature search spanned four databases without time restrictions, assessing various outcomes like success rate, onset time, duration of analgesia and complication rates. Quality assessment employed the Cochrane Collaboration's risk of bias tool, and statistical analyses included heterogeneity assessment, fixed-effect and random-effects models, sensitivity analysis and publication bias evaluation using funnel plots and Egger's linear regression test. From an initial pool of 1213 articles, six met the inclusion criteria. The subsheath group showed a significantly higher success rate of complete sensory blockade within 30 min compared with the extrasheath group (OR = 5.39; 95% CI: 2.82-10.28; p < 0.01). No significant differences were found in procedure duration or incidence of nerve-related complications between the two techniques. The subsheath approach also demonstrated a quicker onset time of sensory blockade (MD = -8.57; 95% CI: -11.27 to -5.88; p < 0.01). Sensitivity analysis confirmed the stability of the results, and no significant publication bias was detected. Ultrasound-guided subsheath sciatic nerve blocks are more effective than extrasheath blocks in achieving rapid and complete sensory blockade for tibial and foot surgeries, with a quicker onset time and comparable safety profile. Subsheath injections are thus recommended as a preferred method for anaesthesia and postoperative pain management in these surgical procedures, enhancing overall patient outcomes.
PROBLEM TO BE SOLVED: To obtain an antifungal agent having antifungal activity and useful for various areas, e.g. foods, medicines, construction materials, paints, agriculture and horticulture, and feeds for stock and fish breeding by using insect-derived peptide with a specific amino acid sequence as the active component. SOLUTION: This antifungal agent contains, as the active component, moricin as insect-derived peptide, composed of the amino acid sequence shown by the formula, or peptide or the like composed of the amino acid sequence shown by the formula wherein one or more amino acids are added, missing or substituted, and having antifungal activity. It can be directly used, or formed into tablet, powder, water dispersible powder, emulsifier or capsule shape after it is mixed with, e.g. solid carrier, liquid carrier or emulsifying dispersant which is normally used. It is useful for various areas, e.g. foods, medicines, construction materials, paints, agriculture and horticulture, and feeds for stock and fish breeding.
In this study we aim to determine if clinical response and toxicity of radiotherapy hypofractionation is non-inferior to the conventional treatment. We will enroll 60 eligible patients with cervical cancer stage IB to IIIC and randomly allocate them into the intervention (hypofractionation) group or the control (standard) groups. The patients in the intervention group will receive external beam radiotherapy(EBRT) to a total dose of 40 Gy in 15 fractions within 3 weeks concurrently with weekly chemotherapy with cisplatin 40mg/m2 (total of 3 cycles). Whereas, the control group will receive EBRT to a total dose of 45 Gy in 25 fractions within 5 weeks concurrently with weekly chemotherapy with cisplatin 40mg/m2 (total of 5 cycles). All patients from both groups will undergo high dose rate brachytherapy one week after completion of EBRT to a total dose of 28 Gy per 4 weekly sessions. Patients will be evaluated regarding early and late toxicities as described by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 at the completion of brachytherapy, and at 3 months, 6 months, and 3 years from completion of treatment. Also, clinical response will be evaluated through dynamic contrast enhanced pelvic MRI 3 months, 1 year, and 3 years after completion of brachytherapy.
This protocol aims to gather information about sphingosine phosphate lyase insufficiency syndrome (SPLIS), a condition also known as NPHS14 or familial steroid-resistant nephrotic syndrome with adrenal insufficiency. SPLIS is a recently discovered genetic disease caused by recessive mutations in the SGPL1 gene. SPLIS can have effects on the kidney, adrenal gland, brain, skin, and blood cells. Some patients with SPLIS do not survive beyond infancy, whereas others live to adulthood. By monitoring the natural history of SPLIS over time in affected patients, the investigators will establish a clinical baseline that reflects how the disease progresses over time. This information may be useful in future clinical trials. The results may reveal which types of SGPL1 mutations correlate with best and worst patient outcomes. Some SPLIS patients are current on a regimen of high dose vitamin B6 supplementation on the advice of their treating physician. By including patients treated with B6, our study may provide evidence for the impact of B6 treatment on biochemical and blood markers of the disease. Our overall goals are to characterize the clinical, biochemical and metabolic manifestations of SPLIS and how these manifestations change over time within individuals with this condition.
A method for identifying medical diverters includes identifying users having similar job functions. Use data indicative of user access to a medication dispensing system is retrieved and is analyzed to identify periods of use of the system for users. Boundaries of work shifts are determined and users are organized into work shifts based on periods of use. A comparison period is determined. Diversion data indicative of behavior associated with diversion for each user is identified. A diversion score indicative of a likelihood that a user is diverting medication is generated by averaging the data by shifts worked for each user and statistically comparing the averaged data. Diversion scores are combined for a medication type to generate a group score. A consistency factor is determined and an overall score is generated. A determination whether any overall scores exceed an overall threshold is made. Users whose score exceeds the threshold are flagged.
PURPOSE: A system and method for managing a medical insurance using a medical insurance electronic recording medium and a communication network is provided to store on-line connection information, personal history information, and medical examination history information electrically for a medical insurance receiver to use a medical insurance and to permit a medical examination of a medical institution using a medical insurance benefit through on-line connection information. CONSTITUTION: A card type information recording medium having a semiconductor memory is provided. The semiconductor memory stores medical insurance related information of a medical insurance receiver capable of being read to the exterior. A smart media medical insurance card(2) is embodied to a medical insurance receiver. A local terminal(4) for a medical institution is mounted in a plurality of medical institutions. A display monitor(12), a key input unit(14), a card read/recording unit(16) and a sign certification input unit(18) are connected to the local terminal(4). A switching hub(20) and a secure encryption/compression processing unit(24) connect the local terminal(4) and an internal network to the Internet network and an on-line as an information communication network.
An mRNA for treating osteoarthritis, a preparation method therefor, and use thereof. Firstly, an mRNA is provided, and can encode an amino acid having a sequence set forth in SEQ ID No. 12. Further provided is a preparation method for the mRNA. Further provided is a pharmaceutical formulation for treating articular cartilage injury and/or osteoarthritis, comprising the mRNA. Further provided is use of the mRNA and an osteoarthritis pharmaceutical formulation in an mRNA dosage form. The specific expression level of the provided mRNA in cells is higher; after intramuscular injection, a TNFα level in mouse serum is significantly lower; the therapeutic effect is better.
FIELD: veterinary virology, biotechnology. SUBSTANCE: method involves preparing virus-containing material from the strain "VNIVIP-DEP" and the following purification of virus-containing material is carried out by method of molecular-sieve chromatography on macroporous glass with pore diameter corresponding to diameter of virus virion to be purified. The best result is obtained using macroporous glass modified with polyvinylpyrrolidone with pore diameter 1200  , not less. Then method involves adsorption of highly purified antigen in the protein concentration 5-10 mcg/0.1 cm 3 , not less. Antispecies immunoperoxidase conjugate raised against to chicken IgG is used as conjugate. In carrying out spectrophotometric recording results in assay of final titer of sample to be analyzed by a single dilution 1:100 the following equation is used: lg titer = 2.19 x (LgS/P) + 3.59 where S/P = (S-NKx)/(PKx + NKx); S means value of optical density of analyzed serum; P means value of optical density of positive control; NKx means an average value of optical density of negative control; PKx means an average value of optical density of positive control. Invention can be used for determination of specific antibodies raised to chicken tenosynovitis reovirus by method of immunoenzyme analysis. EFFECT: enhanced sensitivity and specificity of analysis. 4 cl, 2 tbl
Photobiomodulation (PBM), also known as low-level laser therapy, is a non-invasive light therapy that applies near-infrared light sources near target tissues. PBM allows photons to penetrate tissues and interact with cells, promoting photophysical and chemical changes that result in desired changes at the molecular, cellular, and tissue levels (Oliveira et al., 2022; Shetty et al., 2023). This complementary therapy has garnered significant research attention both domestically and internationally. The results of recent research indicate non-invasive transcranial light stimulation can enhance high-frequency oscillations such as α and β waves, leading potentially to improved cognitive and neurological functions, memory, attention, and emotional status in healthy adults (Shetty et al., 2023). This mode of therapy is recommended as a non-pharmacological intervention for pain relief (Ross, 2022) and has been found to improve oral pain and quality of life in patients with burning mouth syndrome and in those undergoing hematopoietic stem cell transplantation (Camolesi et al., 2022; Chan et al., 2023). Also, PBM has been promoted as a method of enhancing wound healing (Oliveira et al., 2022) and of reducing the respiratory disturbance index in patients with obstructive sleep apnea (de Camargo et al., 2020). Researchers in Taiwan have also applied PBM to alleviate the pain associated with heel prick blood sampling in newborns and suggested using low-level laser therapy as a pain relief measure for full-term newborns undergoing invasive procedures (Wu et al., 2023). For the column in this issue, we have invited domestic nursing and optoelectronic scholars who have conducted extensive research in the field of PBM to explain the related mechanisms, share research findings, and introduce PBM devices that may be used in clinical, home, and school settings. Considering the impact of shift work on sleep among healthcare professionals, we also hope to provide nurses with different insights and options for self-care and patient care through the research and product introductions provided. Finally, an article on assessing aging and promoting health from a traditional Chinese medicine perspective is included to offer nursing professionals a holistic approach to self-care and preventive concepts based on natural rhythms.
Carefully consider the potential benefits and risks ketorolac tromethamine and other treatment options before deciding to use ketorolac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS).

Acute Pain in Adult Patients

Ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with intravenous or intramuscular dosing of ketorolac tromethamine and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary.

The total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see WARNINGS,PRECAUTIONS, DOSAGE AND ADMINISTRATION, and ADVERSE REACTIONS). Patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine therapy is not to exceed 5 days.
1515445 Injection syringes CONTRAVES AG 28 July 1976 [28 July 1975] 31534/76 Heading A5R [Also in Divisions Fl and F2] A piston member for use in the cylindrical casing 1, Figure 1, of an injection syringe for injecting liquids into blood vessels of living bodies, comprises a cylindrical body 2, a first circumferential groove 12, Figure 2, around the cylindrical surface of the body, a second circumferential groove 14 around the body parallel to the first groove 12, a sealing ring 7 engaged in the second circumferential groove and a sliding ring 6 of approximately L-shaped section engaging with one limb 8 in groove 12 and with the other limb 9 extending along the side of body 2 and at least partially over the sealing ring. A shoulder 17 of body 2 extends radially with respect to the body to define the distal portion of groove 14, and said portion of the groove preferably covers only half of the ring 7 to discourage the adherence of gas-bubbles. A space 13 formed in groove 14 between rings 6 and 7 is filled with elastomeric material. The casing 1 may be made of a transparent plastics material, e.g. a polysulphone, or a polycarbonate, or of a metal. The ring 6 is made of resilient material having a low coefficient of friction e.g. polytetrafluoroethylene or a polyamide. The limb 8 of ring 6 may be made longer to penetrate further into the body 2 if it is also slotted to provide segments which may be pushed apart during assembly of the ring on body 2.